Collectively, these data suggest that NLRP3 inhibitors are potential targets in obesity-induced inflammation and insulin resistance (Vandanmagsar et al., 2011), NAFLD (Henao-Mejia et al., 2012; Wree et al., 2014b) and NASH (Mridha et al., 2017). The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.